PepGen Reports Positive Data from Phase I Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

PepGen, Inc. announced results from its completed Phase I healthy normal volunteer trial of PGN-EDO51, the company’s lead product candidate for the treatment of Duchenne muscular dystrophy patients whose mutations were amenable to an exon 51 skipping approach.